Cargando...

Recombinant activated clotting factor VII (rFVIIa) in the treatment of surgical and spontaneous bleeding episodes in hemophilic patients

Inhibitors against replacement clotting factors occur in approximately 30%–40% of patients with hemophilia A and 1.5%–3% of patients with hemophilia B. In this group of patients, bleeding events are best treated with bypassing agents. Recombinant activated factor VII (rFVIIa) has become the first-li...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Ng, Heng Joo, Lee, Lai Heng
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2006
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1994012/
https://ncbi.nlm.nih.gov/pubmed/17323597
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!